drug

Heart Failure Drug Prevents Renal Damage?+

13th April 2008

barry massie Heart Failure Drug Prevents Renal Damage?

Barry Massie
Barry Massie, San Francisco VA Medical Center
COMMENT: Aaron Kugelmass, Henry Ford Hospital, Detroit
The adenosine A1-receptor antagonist rolofylline appears to prevent renal impairment and improve acute heart failure symptoms. Barry Massie and Aaron Kugelmass discussed

Read More+

Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors+

17th March 2008

silvia novello Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors
Silvia Novello

SILVIA NOVELLO, University of Turin
Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello when she presented data on a range of drugs

Read More+

Audio Journal of Oncology in Advance – March 15th, 2008+

16th March 2008

Volume 16 Number 6 (March 15th, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Chemotherapy Foundation Symposium, November 7-10, 2007, New York

david maloney Audio Journal of Oncology in Advance   March 15th, 2008
David Maloney

Nonmyeloablative

Read More+

“Total Therapy” Possible Cure For Multiple Myeloma?+

26th February 2008

bart barlogie Total Therapy Possible Cure For Multiple Myeloma?
Bart Barlogie

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
BART BARLOGIE, University of Arkansas, Little Rock
A treatment known as “total therapy” could cure many patients with multiple myeloma, conference-goers have just heard. The targeted

Read More+

Chronic Lymphocytic Leukemia After Fludarabine Failure+

26th February 2008

john gribben Chronic Lymphocytic Leukemia After Fludarabine Failure
John Gribben

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
JOHN GRIBBEN, Bartholemews Hospital, London
New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as

Read More+

Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer+

15th February 2008

david cunningham Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer
David Cunningham
REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
DAVID CUNNINGHAM, Royal Marsden Hospital, London
The oral agent capeticabine is just as effective as fluorouracil for treating patients whose metastatic colorectal cancer

Read More+

Non Drug Intervention: Better Than Antipsychotic Drugs for Aggressive Challenging Behaviour in Intellectual Disability+

4th January 2008

peter tyrer Non Drug Intervention: Better Than Antipsychotic Drugs for Aggressive Challenging Behaviour in Intellectual Disability
Peter Tyrer

REFERENCE: Lancet 371:57 January 5, 2008
PETER TYRER, Imperial College, W6 8RP London
A randomized study comparing treatment with risperidone, or haloperidol, or placebo to treat patients who have intellectual disability presenting with a syndrome commonly labelled as

Read More+

New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer+

15th December 2007

jose baselga New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
Jose Baselga

JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and

Read More+

New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura+

9th December 2007

terry gernsheimer New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura
Terry Gernsheimer

TERRY GERNSHEIMER, University of Washington Medical Center, Seattle
An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenic purpura or ITP. This was in a placebo controlled phase III trial

Read More+

Long Term Outcomes of Drug Eluting and Bare Metal Stents in Patients Undergoing PCI+

5th November 2007

laura mauri Long Term Outcomes of Drug Eluting and Bare Metal Stents in Patients Undergoing PCI
Laura Mauri
raymond gibbons Long Term Outcomes of Drug Eluting and Bare Metal Stents in Patients Undergoing PCI
Raymond Gibbons

REFERENCE: Late Breaking Special Session, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
LAURA MAURI, Brigham and Woman’s Hospital, Boston Massachusetts
COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester, Minnesota

The largest study to date looking

Read More+

Stable Angina: Add PCI To Medical Therapy If Guided by SPECT-Detected Ischemia? COURAGE Nuclear Sub-Study Results+

5th November 2007

leslee shaw Stable Angina: Add PCI To Medical Therapy If Guided by SPECT Detected Ischemia? COURAGE Nuclear Sub Study Results
Leslee Shaw
daniel jones Stable Angina: Add PCI To Medical Therapy If Guided by SPECT Detected Ischemia? COURAGE Nuclear Sub Study Results
Daniel Jones

REFERENCE: Abstract: Late Breaking Clinical Trials, Session 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
LESLEE SHAW, Emory University, Atlanta
COMMENT: DANIEL JONES, AHA President, University of Mississippi, Jackson

Some patients with stable

Read More+

London School of Hygiene & Tropical Medicine Audio News Review, August 31st, 2007+

31st August 2007

philippe mayaud London School of Hygiene & Tropical Medicine Audio News Review, August 31st, 2007
Philippe Mayaud

Herpes Simplex Therapy Reduces HIV Activity in Co-Infected Patients

REFERENCE: N Engl J Med 2007; 356: 790-9
PHILIPPE MAYAUD, London School of Hygiene and Tropical Medicine
It is possible to reduce HIV activity in patients who are co-infected

Read More+